FDA-Approved Appetite Suppressants for Weight Loss
Semaglutide 2.4 mg should be prioritized as first-line pharmacotherapy for weight loss in adults with obesity or overweight with weight-related complications, given its superior efficacy and favorable cardiovascular profile. 1
Medication Hierarchy
The most recent 2025 AACE guidelines stratify obesity medications into first-generation and second-generation agents, with semaglutide and tirzepatide representing second-generation, more effective options that should be prioritized when accessible 2.
First-Line: GLP-1 Receptor Agonists
Semaglutide 2.4 mg (Wegovy)
- Dosing: Start 0.25 mg subcutaneously weekly, escalate monthly (0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg maintenance)
- Efficacy: Produces the greatest weight loss among approved medications
- Monitoring: Assess for nausea/vomiting (most common), monitor for pancreatitis and gallbladder disease
- Contraindications: Personal/family history of medullary thyroid carcinoma, MEN2 syndrome, pregnancy/breastfeeding
- Key advantage: Glucoregulatory benefits, approved for T2DM, gradual titration mitigates GI side effects 1
Liraglutide 3.0 mg (Saxenda)
- Dosing: Start 0.6 mg daily subcutaneously, increase by 0.6 mg weekly to 3.0 mg maintenance
- Similar profile to semaglutide but requires daily injection and produces less weight loss
- Same monitoring and contraindications as semaglutide 1
Second-Line: Combination Agents
Phentermine/Topiramate ER (Qsymia)
- Dosing: Start 3.75 mg/23 mg daily for 14 days, then 7.5 mg/46 mg daily; can escalate to 15 mg/92 mg maximum
- Efficacy: Moderate weight loss (5.9-11.5% in trials)
- Monitoring: Blood pressure and heart rate periodically; check for hypokalemia, metabolic acidosis, nephrolithiasis
- Contraindications: Pregnancy (REMS program required—monthly pregnancy testing mandatory), glaucoma, untreated hyperthyroidism, cardiovascular disease, uncontrolled hypertension
- Preferred for: Patients with comorbid migraines 1, 2
- Critical pitfall: Topiramate is highly teratogenic—pregnancy prevention is non-negotiable 2
Naltrexone/Bupropion ER (Contrave)
- Dosing: Start 8 mg/90 mg once daily, escalate weekly by one tablet to 16 mg/180 mg twice daily (32 mg/360 mg total daily)
- Efficacy: 5.9-11.5% weight loss in completers
- Monitoring: Blood pressure and heart rate, especially first 12 weeks
- Contraindications: Seizure disorders, concurrent opioid use, pregnancy/breastfeeding
- Preferred for: Patients attempting smoking cessation or with comorbid depression 1, 2
- Critical pitfall: Avoid with fatty meals (increases drug levels); cannot use with opioids 2
Third-Line Options
Phentermine (monotherapy)
- Dosing: 15-37.5 mg daily
- FDA-approved for short-term use only (<12 weeks), though AGA conditionally recommends with lifestyle modifications 1
- Monitoring: Blood pressure and heart rate
- Lower cost option but less evidence for long-term use 2
Orlistat (Xenical, Alli)
- AGA suggests AGAINST routine use due to minimal weight loss benefit and significant GI adverse effects 1
- Dosing: 120 mg three times daily with meals
- Monitoring: Requires daily multivitamin with fat-soluble vitamins (A, D, E, K) taken 2 hours apart from orlistat
- Only consider if: Patient highly values small weight loss and tolerates GI effects 1
Clinical Algorithm for Selection
Start with semaglutide 2.4 mg for most patients—greatest efficacy and cardiovascular benefits 1
If cost-prohibitive or GLP-1 intolerant, use step-therapy approach with first-generation agents 2:
- Migraines present: Phentermine/topiramate ER
- Depression or smoking cessation: Naltrexone/bupropion ER
- Cardiovascular disease/uncontrolled HTN: Avoid phentermine-containing products; use naltrexone/bupropion ER or liraglutide
Absolute contraindications across all agents: Pregnancy and breastfeeding 2
Universal Monitoring Requirements
- Baseline: Pregnancy test (women of childbearing potential), blood pressure, heart rate, comprehensive metabolic panel
- Ongoing:
- Blood pressure and heart rate with sympathomimetic agents (phentermine-containing, naltrexone/bupropion)
- Signs/symptoms of pancreatitis and gallbladder disease with GLP-1 RAs
- Electrolytes with phentermine/topiramate (hypokalemia, metabolic acidosis)
- Monthly pregnancy testing with phentermine/topiramate ER 1, 2
Critical Pitfalls to Avoid
- Do not use phentermine/topiramate without REMS compliance—teratogenicity risk is substantial 2
- Do not combine naltrexone/bupropion with opioids—blocks opioid efficacy 1
- Do not prescribe GLP-1 RAs without counseling on pancreatitis/gallbladder symptoms—increased risk documented 1
- Do not use phentermine-containing products in uncontrolled hypertension or cardiovascular disease 1
- All medications require long-term use—obesity is a chronic disease requiring sustained treatment 3